{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.8","value":"342"},{"groupId":"OG001","spread":"54.4","value":"297"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"title":"Decitabine: Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.4","value":"30.6"},{"groupId":"OG001","spread":"55.5","value":"28.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"title":"Cedazuridine: Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"159","value":"25.6"},{"groupId":"OG001","spread":"45.4","value":"27.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"Cedazuridine: Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.9","value":"16.8"},{"comment":"Geometric Coefficient of Variation could not be calculated as data for only one participant was available for analysis.","groupId":"OG001","spread":"NA","value":"86.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cedazuridine: Day 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"description":"Oral CL/F for oral decitabine was measured only on Day 1 and oral CL/F for oral cedazuridine was measured on Days 1, 2 and 5. Summarized data of Oral CL/F for oral decitabine on Day 1 for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of oral CL/F for oral cedazuridine on Day 1,2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, given by mouth, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days). From cycle 3, participants received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG000","title":"MDS or CMML: ASTX727"},{"description":"Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, given by mouth, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days). From cycle 3, participants received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG001","title":"AML: ASTX727"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Overall PK Analysis Set included participants not included in Primary Endpoint PK Analysis Set, received any amount of study treatment, complied with protocol sufficiently to ensure PK samples were collected, provided sufficient samples to measure available plasma concentrations for decitabine. Overall number of participants analyzed:Number of participants evaluable for this outcome measure. Number analyzed:Number of participants evaluable for this outcome measure at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)","title":"Apparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine","type":"SECONDARY","unitOfMeasure":"Litres per hour (L/h)"}